The Epidemiology of Neuroendocrine Tumors in Taiwan: A Nation-Wide Cancer Registry-Based Study
Open Access
- 22 April 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4), e62487
- https://doi.org/10.1371/journal.pone.0062487
Abstract
The epidemiology of neuroendocrine tumors (NETs) is not well illustrated, particularly for Asian countries. The age-standardized incidence rates and observed survival rates of NETs diagnosed in Taiwan from January 1, 1996 to December 31, 2008 were calculated using data of the Taiwan Cancer Registry (TCR) and compared to those of the Norwegian Registry of Cancer (NRC) and the US Surveillance, Epidemiology, and End Results (SEER) program. During the study period, a total of 2,187 NET cases were diagnosed in Taiwan, with 62% males and a mean age of 57.9 years-old. The age-standardized incidence rate of NETs increased from 0.30 per 100,000 in 1996 to 1.51 per 100,000 in 2008. The most common primary sites were rectum (25.4%), lung and bronchus (20%) and stomach (7.4%). The 5-year observed survival was 50.4% for all NETs (43.4% for men and 61.8% for women, P<0.0001). The best 5-year observed survivals for NETs by sites were rectum (80.9%), appendix (75.7%), and breast (64.8%). Compared to the data of Norway and the US, the age-standardized incidence rate of NETs in Taiwan is lower and the major primary sites are different, whereas the long-term outcome is similar. More studies on the pathogenesis of NETs are warranted to devise preventive strategies and improve treatment outcomes for NETs.Keywords
This publication has 33 references indexed in Scilit:
- Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter StudyCancer Research and Treatment, 2012
- Altered expression of microRNA miR-21, miR-155, and let-7a and their roles in pulmonary neuroendocrine tumorsPathology International, 2012
- Using the Mitosis-Specific Marker Anti–Phosphohistone H3 to Assess Mitosis in Pulmonary Neuroendocrine CarcinomasAmerican Journal of Clinical Pathology, 2011
- Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumorsExperimental and Therapeutic Medicine, 2011
- Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)Annals Of Oncology, 2010
- High‐grade neuroendocrine carcinoma of the lung: Comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinomaPathology International, 2009
- Evaluation of data quality in the cancer registry: Principles and methods. Part I: Comparability, validity and timelinessEuropean Journal Of Cancer, 2009
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II StudyJournal of Clinical Oncology, 2008
- Survival From Malignant Digestive Endocrine Tumors in England and Wales: A Population-Based StudyGastroenterology, 2007
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003